What the FDA labels say about taking them together
Glecaprevir/pibrentasvir and pitavastatin
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names pitavastatin in its drug interactions section; the pitavastatin labels PlainMeds reads (2) do not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “Coadministration may increase the concentrations of fluvastatin and pitavastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the pitavastatin FDA label on DailyMed (effective March 31, 2026, Kowa Pharmaceuticals America, Inc.).
What does the glecaprevir/pibrentasvir label say about pitavastatin?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Fluvastatin Pitavastatin; Effect on Concentration: ↑ fluvastatin ↑ pitavastatin; Clinical Comments: Coadministration may increase the concentrations of fluvastatin and pitavastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Use the lowest approved dose of fluvastatin or pitavastatin. If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What does the pitavastatin label say about glecaprevir/pibrentasvir?
Pitavastatin's label (effective March 31, 2026) and its 1 other brand-application label do not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Livalo), Kowa Pharmaceuticals America, Inc., effective March 31, 2026 (SPL set 44dcbf97-99ec-427c-ba50-207e0069d6d2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glecaprevir/pibrentasvir | Pitavastatin | |
|---|---|---|
| Labeled for | Hepatitis C | High cholesterol |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.98 per tablet 100-40 mg tablet | $0.954 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once